Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021

What is already known about this topic? SARS-CoV-2 variants have the potential to affect transmission, disease severity, diagnostics, therapeutics, and natural and vaccine-induced immunity. What is added by this report? CDC’s genomic surveillance for SARS-CoV-2 variants generates population-based es...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2021-06, Vol.70 (23), p.846-850
Main Authors: Paul, Prabasaj, France, Anne Marie, Aoki, Yutaka, Batra, Dhwani, Biggerstaff, Matthew, Dugan, Vivien, Galloway, Summer, Hall, Aron J, Johansson, Michael A, Kondor, Rebecca J, Halpin, Alison Laufer, Lee, Brian, Lee, Justin S, Limbago, Brandi, MacNeil, Adam, MacCannell, Duncan, Paden, Clinton R, Queen, Krista, Reese, Heather E, Retchless, Adam C, Slayton, Rachel B, Steele, Molly, Tong, Suxiang, Walters, Maroya S, Wentworth, David E, Silk, Benjamin J
Format: Article
Language:English
Subjects:
Coronaviruses
COVID-19
COVID-19 vaccines
Disease transmission
Full Report
Genomics
Health aspects
Infections
Jurisdiction
Medical laboratories
Monoclonal antibodies
Pandemics
Public health
Regions
Regression analysis
Severe acute respiratory syndrome coronavirus 2
Surveillance
Vaccination
Vaccines
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:What is already known about this topic? SARS-CoV-2 variants have the potential to affect transmission, disease severity, diagnostics, therapeutics, and natural and vaccine-induced immunity. What is added by this report? CDC’s genomic surveillance for SARS-CoV-2 variants generates population-based estimates of the proportions of variants among all SARS-CoV-2 infections in the United States. During April 11–24, 2021, the B.1.1.7 and P.1 variants represented an estimated 66.0% and 5.0% of U.S. infections, respectively, demonstrating the potential for new variants to emerge and become predominant. What are the implications for public health practice? Robust genomic surveillance can help guide prevention strategies (e.g., enhanced vaccination coverage efforts) and clinical management decisions (e.g., monoclonal antibody distribution) to control the COVID-19 pandemic in the United States.
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm7023a3